welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.
Date & Time:
December 13, 2019
8:00 AM to 4:00 PM
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland, United States
This event has ended.
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of LifeHorizon Therapeutics plc today announced...
Contour Variability in Thyroid Eye Disease With Compressive Optic Neuropathy Treated With Radiation TherapyPurpose: Few studies have evaluated t...
Pathogenesis of Thyroid Eye Disease: Review and Update on Molecular MechanismsOrbital changes in thyroid orbitopathy (...
Graves’ Orbitopathy: Reevaluating Rundle’s CurveGraves’ orbitopathy (GO) is the most c...
Raymond Douglas, MD, PhDDr. Raymond Douglas is the Director of t...
Teprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
Efficacy of Orbital Radiotherapy in Moderate-to-Severe Active Graves’ Orbitopathy Including Long-Lasting Disease: ...Background: We aimed to explore the eff...